Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia.

Adult Humans Transplantation, Haploidentical / adverse effects Unrelated Donors Transplantation Conditioning / methods Graft vs Host Disease / etiology Retrospective Studies Cyclophosphamide / therapeutic use Hematopoietic Stem Cell Transplantation / methods Leukemia, Myeloid, Acute / drug therapy

Journal

Bone marrow transplantation

ISSN: 1476-5365

Titre abrégé: Bone Marrow Transplant

Pays: England

ID NLM: 8702459

Informations de publication

Date de publication:
11 2022

Historique:

received: 21 04 2022

accepted: 04 08 2022

revised: 03 08 2022

pubmed: 18 8 2022

medline: 5 11 2022

entrez: 17 8 2022

Statut: ppublish

Résumé

HLA-haploidentical allogeneic hematopoietic stem cell transplantation (Haplo-HCT) is frequently used as treatment for patients with active acute myeloid leukemia (AML). Here, we investigated whether 9/10 HLA-mismatched unrelated donor transplantation (MMUD-HCT) with post-transplant cyclophosphamide (PTCy) is an adequate alternative. Inclusion criteria in this retrospective registry study consisted of adult patients, first HCT with a Haplo donor or MMUD between 2010 and 2020 using PTCy as graft-versus-host disease (GVHD) prophylaxis, and primary refractory or relapsed disease. MMUD patients were pair-matched 1 to 2 with Haplo-recipients. A total of 73 MMUD patients met the inclusion criteria. Their data were compared to those of 146 Haplo patients in a matched-pair analysis. Median follow-up was 27 months in MMUD patients and 36 months in Haplo recipients. Two-year incidences of relapse and non-relapse mortality (NRM) were 40% and 18% in MMUD patients, respectively, versus 50% (P = 0.23) and 24% (P = 0.18) in Haplo recipients. Two-year leukemia-free survival (LFS) and overall survival (OS) was 42% and 46% in MMUD recipients, respectively, versus 26% (P = 0.1) and 28% (P = 0.061) in Haplo-patients. In conclusions, in AML patients with active disease at transplantation, MMUD-HCT results in at least comparable outcomes to Haplo-HCT when PTCy is applied.

Identifiants

DOI: 10.1038/s41409-022-01781-9 PMID: 35978005

pubmed: 35978005

doi: 10.1038/s41409-022-01781-9

pii: 10.1038/s41409-022-01781-9

doi:

Substances chimiques

Cyclophosphamide 8N3DW7272P

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

1657-1663

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Références

Baron F, Stevens-Kroef M, Kicinski M, Meloni G, Muus P, Marie J-P, et al. Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype. Haematologica. 2019;104:1168–75.

pubmed: 30523055 pmcid: 6545848 doi: 10.3324/haematol.2018.204826

Baron F, Efficace F, Cannella L, Muus P, Trisolini S, Halkes CJM, et al. Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukemia: Long-term follow up of a phase III study. Am J Hematol. 2020;95:749–58.

pubmed: 32233095 doi: 10.1002/ajh.25795

Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132:1703–13.

pubmed: 30190321 doi: 10.1182/blood-2018-02-829911

Versluis J, In’t Hout FEM, Devillier R, van Putten WLJ, Manz MG, Vekemans M-C et al. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. Leukemia. 2017;31:26–33..

Zhang X-H, Chen J, Han M-Z, Huang H, Jiang E-L, Jiang M, et al. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol OncolJ Hematol Oncol. 2021;14:145.

pubmed: 34526099 pmcid: 8441240 doi: 10.1186/s13045-021-01159-2

Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

pubmed: 27895058 pmcid: 5291965 doi: 10.1182/blood-2016-08-733196

Baron F, Labopin M, Ruggeri A, Ehninger G, Bonifazi F, Stelljes M, et al. Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT. Blood Cancer J. 2019;9:46.

pubmed: 30979868 pmcid: 6461673 doi: 10.1038/s41408-019-0204-x

Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J, et al. Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. J Hematol OncolJ Hematol Oncol. 2017;10:130.

pubmed: 28646908 pmcid: 5483262 doi: 10.1186/s13045-017-0498-8

Battipaglia G, Boumendil A, Labopin M, Ciceri F, Tischer J, Stelljes M, et al. Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT. Bone Marrow Transpl. 2019;54:1499–510.

doi: 10.1038/s41409-019-0459-7

Milano F, Gooley T, Wood B, Woolfrey A, Flowers ME, Doney K, et al. Cord-blood transplantation in patients with Minimal Residual Disease. N. Engl J Med. 2016;375:944–53.

pubmed: 27602666 pmcid: 5513721 doi: 10.1056/NEJMoa1602074

Baron F, Ruggeri A, Beohou E, Labopin M, Mohty M, Sanz J, et al. Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT. J Intern Med. 2018;283:178–89.

pubmed: 28977716 doi: 10.1111/joim.12696

Baron F, Labopin M, Ruggeri A, Cornelissen JJ, Meijer E, Sengeloev H, et al. Impact of Donor Type in patients with AML given Allogeneic Hematopoietic Cell Transplantation after low-dose TBI-Based Regimen. Clin Cancer Res J Am Assoc Cancer Res. 2018;24:2794–803.

doi: 10.1158/1078-0432.CCR-17-3622

Baron F, Ngoya M, Labopin M, Cornelissen JJ, Ganser A, Forcade E, et al. Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT. Bone Marrow Transplant. 2021. https://doi.org/10.1038/s41409-021-01387-7 .

Luznik L, Engstrom LW, Iannone R, Fuchs EJ. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2002;8:131–8.

doi: 10.1053/bbmt.2002.v8.pm11939602

Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13:132.

pubmed: 26718103 doi: 10.1038/nrclinonc.2015.234

Sanz J, Galimard J-E, Labopin M, Afanasyev B, Angelucci E, Ciceri F, et al. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol J Hematol Oncol. 2020;13:46.

pubmed: 32375860 pmcid: 7201995 doi: 10.1186/s13045-020-00882-6

Cytryn S, Abdul-Hay M. Haploidentical Hematopoietic Stem Cell Transplantation Followed by ‘Post-Cyclophosphamide’: The Future of Allogeneic Stem Cell Transplant. Clin Hematol Int. 2020;49–58.

Brissot E, Labopin M, Moiseev I, Cornelissen JJ, Meijer E, Van Gorkom G, et al. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. J Hematol Oncol J Hematol Oncol. 2020;13:87.

pubmed: 32620146 pmcid: 7333262 doi: 10.1186/s13045-020-00923-0

Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, et al. National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol J Am Soc Clin Oncol. 2021;39:1971–82.

doi: 10.1200/JCO.20.03502

Kasamon YL, Ambinder RF, Fuchs EJ, Zahurak M, Rosner GL, Bolaños-Meade J, et al. Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. Blood Adv. 2017;1:288–92.

pubmed: 29242852 pmcid: 5726600 doi: 10.1182/bloodadvances.2016002766

Battipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood. 2019;134:892–9.

pubmed: 31270102 doi: 10.1182/blood.2019000487

Dholaria B, Labopin M, Sanz J, Ruggeri A, Cornelissen J, Labussière-Wallet H, et al. Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia. J Hematol Oncol J Hematol Oncol. 2021;14:76.

pubmed: 33941226 pmcid: 8094558 doi: 10.1186/s13045-021-01086-2

Soltermann Y, Heim D, Medinger M, Baldomero H, Halter JP, Gerull S, et al. Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study. Ann Hematol. 2019;98:1485–93.

pubmed: 30915500 doi: 10.1007/s00277-019-03673-3

Nagler A, Kanate AS, Labopin M, Ciceri F, Angelucci E, Koc Y, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia. Haematologica. 2021;106:1591–8.

pubmed: 32354866 doi: 10.3324/haematol.2020.247296

Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.

pubmed: 15994282 pmcid: 1895304 doi: 10.1182/blood-2005-05-2004

Poiani M, Labopin M, Battipaglia G, Beelen DW, Tischer J, Finke J, et al. The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT). Am J Hematol. 2021;96:40–50.

pubmed: 32944990 doi: 10.1002/ajh.26000

Nagler A, Labopin M, Canaani J, Niittyvuopio R, Socié G, Kröger N, et al. Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation. Am J Hematol. 2020. https://doi.org/10.1002/ajh.25905 .

Rodríguez-Arbolí E, Labopin M, Tischer J, Brecht A, Ganser A, Finke J, et al. FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2020;26:2165–73.

doi: 10.1016/j.bbmt.2020.07.020

Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transpl. 2016;51:610–1.

doi: 10.1038/bmt.2015.305

Baron F, Ruggeri A, Beohou E, Labopin M, Mohty M, Blaise D, et al. Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. J Hematol Oncol J Hematol Oncol. 2017;10:128.

pubmed: 28637512 pmcid: 5479038 doi: 10.1186/s13045-017-0497-9

Abraham AS, Nagler A, Savani B. Summary of Scientific and Statistical Methods, Study Endpoints and Definitions for Observational and Registry-Based Studies in Hematopoietic Cell Transplantation. Clin Hematol Int. 2019;2:2–4.

doi: 10.2991/chi.d.191207.001

Greco R, Lorentino F, Albanese S, Lupo Stanghellini MT, Giglio F, Piemontese S, et al. Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. Transpl Cell Ther. 2021;27:776.e1–13.

doi: 10.1016/j.jtct.2021.05.023

Ehx G, Ritacco C, Hannon M, Dubois S, Delens L, Willems E, et al. Comprehensive Analysis of the Immunomodulatory Effects of Rapamycin on Human T Cells in Graft-versus-Host Disease Prophylaxis. Am J Transpl J Am Soc Transpl Am Soc Transpl Surg. 2021;21:2662–74.

doi: 10.1111/ajt.16505

Yu S, Huang F, Fan Z, Xuan L, Nie D, Xu Y, et al. Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data. J Hematol Oncol J Hematol Oncol. 2020;13:18.

pubmed: 32164760 pmcid: 7068952 doi: 10.1186/s13045-020-00859-5

Ruggeri A, Labopin M, Bacigalupo A, Gülbas Z, Koc Y, Blaise D, et al. Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. Cancer. 2018;124:1428–37.

pubmed: 29360162 doi: 10.1002/cncr.31228

Bashey A, Zhang M-J, McCurdy SR, St Martin A, Argall T, Anasetti C, et al. Mobilized peripheral blood stem cells versus unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol J Am Soc Clin Oncol. 2017;35:3002–9.

doi: 10.1200/JCO.2017.72.8428

Nagler A, Dholaria B, Labopin M, Savani BN, Angelucci E, Koc Y, et al. Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. Leukemia. 2020;34:2766–75.

pubmed: 32393841 doi: 10.1038/s41375-020-0850-9

Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P, et al. Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transpl Cell Ther. 2021;27:1003.e1–1003.e13.

doi: 10.1016/j.jtct.2021.09.003

Baron F, Labopin M, Tischer J, Ciceri F, Raiola AM, Blaise D, et al. HLA-haploidentical transplantation for relapsed/refractory AML: better LFS with BM than with PBSC in patients ≥ 55 years of age. Am J Hematol. 2022. https://doi.org/10.1002/ajh.26627 .

Ringdén O, Labopin M, Ciceri F, Velardi A, Bacigalupo A, Arcese W, et al. Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings? Leukemia. 2016;30:447–55.

pubmed: 26293645 doi: 10.1038/leu.2015.232

Rovatti PE, Gambacorta V, Lorentino F, Ciceri F, Vago L. Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation. Front Immunol. 2020;11:147.

pubmed: 32158444 pmcid: 7052328 doi: 10.3389/fimmu.2020.00147

Bazarbachi A, Bug G, Baron F, Brissot E, Ciceri F, Abou Dalle I, et al. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3 internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2020. https://doi.org/10.3324/haematol.2019.243410 .

Ehx G, Fransolet G, de Leval L, D’Hondt S, Lucas S, Hannon M, et al. Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects. Oncoimmunology. 2017;6:e1314425.

pubmed: 28638744 pmcid: 5467988 doi: 10.1080/2162402X.2017.1314425

Gao L, Zhang Y, Wang S, Kong P, Su Y, Hu J, et al. Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial. J Clin Oncol J Am Soc Clin Oncol. 2020;38:4249–59.

doi: 10.1200/JCO.19.03277

Schmid C, Labopin M, Schaap N, Veelken H, Schleuning M, Stadler M, et al. Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT. Br J Haematol. 2019;184:782–7.

pubmed: 30467839 doi: 10.1111/bjh.15691

Schmid C, Labopin M, Schaap N, Veelken H, Brecht A, Stadler M, et al. Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. Bone Marrow Transplant. 2021. https://doi.org/10.1038/s41409-021-01515-3 .

Dholaria B, Savani BN, Labopin M, Luznik L, Ruggeri A, Mielke S, et al. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. Haematologica. 2020;105:47–58.

pubmed: 31537691 pmcid: 6939532 doi: 10.3324/haematol.2019.219790

Schmid C, Labopin M, Socie G, Daguindau E, Volin L, Huynh A, et al. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Blood. 2015;126:2062–9.

pubmed: 26351297 doi: 10.1182/blood-2015-06-651562

Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2016;51:906–12.

doi: 10.1038/bmt.2016.130

Mohty M, Malard F, Abecasis M, Aerts E, Alaskar AS, Aljurf M, et al. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transpl. 2020;55:485–95.

doi: 10.1038/s41409-019-0705-z